Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.68)
# 748
Out of 5,072 analysts
42
Total ratings
57.14%
Success rate
6.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $5.28 | +51.52% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $18.63 | +77.13% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $12.42 | +20.77% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $9.64 | +86.72% | 4 | Nov 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Overweight | $15 | $4.62 | +224.68% | 1 | Oct 28, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $28.99 | +20.73% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.68 | +123.88% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $35.88 | +25.42% | 3 | Sep 9, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $17.20 | +74.42% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $44.21 | +35.72% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $23.43 | +40.85% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $4.33 | +84.76% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $7.31 | +105.20% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $60 | $67.86 | -11.58% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.45 | +244.83% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $8.45 | +1,083.43% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.96 | +920.41% | 1 | May 14, 2024 |
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $5.28
Upside: +51.52%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $18.63
Upside: +77.13%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $12.42
Upside: +20.77%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $9.64
Upside: +86.72%
Candel Therapeutics
Oct 28, 2025
Initiates: Overweight
Price Target: $15
Current: $4.62
Upside: +224.68%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $28.99
Upside: +20.73%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.68
Upside: +123.88%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $35.88
Upside: +25.42%
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $17.20
Upside: +74.42%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $44.21
Upside: +35.72%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $23.43
Upside: +40.85%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $4.33
Upside: +84.76%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.31
Upside: +105.20%
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $67.86
Upside: -11.58%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.45
Upside: +244.83%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $8.45
Upside: +1,083.43%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.96
Upside: +920.41%